Compare RGS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGS | BOLD |
|---|---|---|
| Founded | 1922 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 36.5M |
| IPO Year | 1994 | 2024 |
| Metric | RGS | BOLD |
|---|---|---|
| Price | $26.62 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 4.2K | ★ 85.7K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.24 | ★ 32.47 |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $210,134,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $31.20 | ★ N/A |
| Revenue Growth | ★ 3.52 | N/A |
| 52 Week Low | $18.23 | $0.96 |
| 52 Week High | $31.50 | $1.68 |
| Indicator | RGS | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 46.37 |
| Support Level | $26.06 | $1.40 |
| Resistance Level | $28.51 | $1.53 |
| Average True Range (ATR) | 0.91 | 0.05 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 23.50 | 22.22 |
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.